v3.26.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash flows from operating activities:    
Net loss $ (33,044,000) $ (18,377,000)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 1,373,000 1,530,000
Amortization of intangible assets 20,000 20,000
Amortization of finance lease right-of-use assets 68,000 271,000
Amortization of operating lease right-of-use assets 384,000 351,000
Depreciation of fixed assets 558,000 484,000
Accrued interest receivable on promissory note receivable (80,000) (62,000)
Amortization of premiums/(accretion of discounts) on debt securities, net (194,000) 0
Provision for credit losses 65,000  
Impairment of fixed assets 107,000  
Impairment of intangible assets 5,003,000  
Changes in operating assets and liabilities:    
Accounts receivable - trade (65,000)  
Prepaid expenses and other current assets (2,153,000) (408,000)
Prepaid expenses - noncurrent (73,000)  
Security deposit 16,000  
Accounts payable 2,223,000 1,831,000
Accrued expenses 3,114,000 (758,000)
Operating lease obligations (490,000) (436,000)
Contract liabilities (50,000) 250,000
Net cash used in operating activities (23,218,000) (15,304,000)
Cash flows from investing activities:    
Purchases of debt securities (42,296,000)  
Redemption of debt securities 10,800,000  
Payment received for interest and principal on promissory note receivable 75,000 758,000
Purchases of fixed assets (578,000) (16,000)
Net cash (used in) provided by investing activities (31,999,000) 742,000
Cash flows from financing activities:    
Proceeds from sales of common stock 3,529,000 3,541,000
Proceeds from sales of pre-funded warrants 72,682,000  
Proceeds from the exercise of warrants for pre-funded warrants 18,076,000  
Proceeds from the exercise of warrants for common stock 15,290,000  
Payments made for costs to acquire capital (5,860,000) (294,000)
Proceeds from Warrant Inducement Transaction   6,246,000
Proceeds from the exercise of stock options   130,550
Subscription receivable 105,000  
Payment of equipment financing loan (64,000) (178,000)
Payment of term promissory note (657,000) (218,000)
Payment of finance lease obligation (53,000) (299,000)
Net cash provided by financing activities 103,048,000 8,929,000
Net increase (decrease) in cash, cash equivalents and restricted cash 47,831,000 (5,633,000)
Cash, cash equivalents and restricted cash - beginning 8,792,000 14,425,000
Cash, cash equivalents and restricted cash - end 56,623,000 8,792,000
Schedule of non-cash activities:    
Costs to raise capital included in accrued expenses 1,173,000 50,000
Reserves related to term promissory note included in prepaid expenses (109,000)  
Unrealized loss on available-for-sale debt securities 45,000  
Unpaid fixed assets in accounts payable 11,000  
Indefinite-lived intangible asset addition   1,500,000
Shares issued to AstralBio for license fee   (750,000)
Credit provided by AstralBio   (750,000)
Subscription receivable   105,000
Costs to raise capital paid directly from gross proceeds   81,000
Supplemental cash flow information:    
Cash paid during the year for interest $ 72,000 $ 212,000